ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.
相关临床试验
20
9 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2020
进行中（未招募）
9
45.0%
已完成
6
30.0%
招募中
2
10.0%
终止
3
15.0%
暂无批准数据
- Alumis completed an upsized public offering of 17.65 million shares at $17 per share, raising approximately $300 million in gross proceeds to fund its clinical-stage pipeline. - The company is simultaneously pursuing a merger with ACELYRIN that would create a combined entity with approximately $737 million in pro forma cash and runway into 2027. - The merged company will focus on immune-mediated diseases with key milestones including Phase 3 data for ESK-001 in psoriasis expected in Q1 2026 and Phase 2b lupus data in 2026. - Alumis stockholders will own 55% of the combined company while ACELYRIN stockholders will receive 0.4274 Alumis shares for each ACELYRIN share owned.
- ResearchAndMarkets.com released a comprehensive report analyzing 1,775 clinical-stage partnering deals in pharma and biotech from 2020-2025, providing detailed financial terms and strategic insights. - The report includes headline values, upfront payments, milestone structures, and royalty ranges for Phase I-III partnerships, with direct access to SEC-filed contracts where available. - Clinical-stage licensing agreements typically grant exclusive rights covering Phase I, Phase II, and Phase III trials, often involving collaborative R&D and co-development strategies. - The analysis profiles the top 25 most active clinical-stage dealmakers and examines the highest-value partnerships to help companies benchmark terms and optimize negotiation strategies.
- Elevation Oncology has agreed to be acquired by Concentra Biosciences, controlled by hedge fund Tang Capital Partners, for $0.36 per share in cash with additional contingent value rights. - The acquisition represents the latest example of investment firms targeting struggling biotech "zombies" worth less than their cash reserves for liquidation rather than strategic repositioning. - Elevation's lead cancer drug disappointed in clinical testing, forcing the company to shelve its program, lay off most staff, and trade below $1 per share for nearly a year. - The deal follows Tang Capital's previous acquisitions of struggling biotechs including Allakos, Jounce Therapeutics, and Kronos Bio through its liquidation-focused investment strategy.
- Third Harmonic Bio stockholders overwhelmingly approved a liquidation and dissolution plan with 99.9% of voting shares supporting the proposal at the June 5, 2025 annual meeting. - The company's oral KIT inhibitor THB335 demonstrated an 85% mean reduction in serum tryptase with encouraging safety profile in a Phase 1 cohort evaluating 100mg daily dosing. - Initial distribution to stockholders is expected between $5.30-$5.35 per share in Q3 2025, with the company initiating a sale process for THB335 and related intellectual property. - The biotech joins other companies choosing dissolution over continued operations after clinical setbacks, with analysts noting this approach may better serve investor interests than prolonged "zombie" status.
• Alumis and Acelyrin have entered into a merger agreement, marking a significant consolidation in the biotechnology sector. • The companies announced the suspension of the planned Phase III program for lonigutamab following disappointing Phase II results reported in January. • The merger decision includes a strategic reassessment of lonigutamab's development program to evaluate its potential value and future direction.
- Alumis and Acelyrin have agreed to merge in an all-stock transaction, creating a combined entity with $737 million in cash runway extending into 2027. - The merged company will retain the Alumis name and prioritize development of two TYK2 inhibitors targeting conditions including psoriasis, lupus, and multiple sclerosis. - Acelyrin's thyroid eye disease drug lonigutamab is included in the deal but will undergo strategic review to assess its market differentiation potential.
• Acelyrin's lonigutamab Phase 1/2 study update reveals that lower doses administered every four weeks were subtherapeutic for thyroid eye disease (TED). • The company's analysis determined that a minimum concentration of 3 ug/ml is required for maximized efficacy, achievable with a 100 mg loading dose followed by 50 mg every two weeks. • Phase 3 program for lonigutamab in TED is set to begin in the first quarter of 2025, utilizing the optimized dosing regimen based on pharmacokinetic data. • H.C. Wainwright adjusted Acelyrin's stock target to $6.00, maintaining a Neutral rating, reflecting the Phase 1/2 study findings and future trial design.
• Acelyrin's lonigutamab demonstrates a potential best-in-class efficacy and safety profile for treating Thyroid Eye Disease (TED), according to updated Phase 2 data. • A virtual investor event on January 6, 2025, will feature clinician perspectives on unmet needs in TED and the design of the Phase 3 LONGITUDE program. • The Phase 3 LONGITUDE program, developed after discussions with the FDA, aims to be the most inclusive registrational program in TED to date. • Lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, offers potential for longer-term, convenient dosing, improving clinical response.
• Acelyrin will present Phase 2 data for subcutaneous Lonigutamab, indicating a potentially best-in-class efficacy and safety profile for Thyroid Eye Disease (TED). • The company plans to unveil the design for its Phase 3 program following a successful meeting with the FDA. • A virtual investor event is scheduled to reveal the data and Phase 3 design, featuring experts from Stanford and the University of Colorado School of Medicine.
- Acelyrin Inc. (SLRN) stock reached a 52-week low amidst challenging market conditions, reflecting broader economic pressures and investor concerns. - The Phase 2b/3 study of izokibep for uveitis treatment failed to meet its primary endpoint, showing no statistically significant difference from placebo. - Acelyrin is advancing its clinical pipeline with lonafarnib for thyroid eye disease and plans to initiate a Phase 3 program for lonigutamab in early 2025. - Despite setbacks, Acelyrin maintains a strong liquidity position, with cash runway expected to extend into mid-2027, and is set to acquire global rights to lonigutamab.
